The epidemic of opioid lawsuits continues to pick-up steam. The latest case is the State of Washington’s latest suit against Johnson & Johnson (“J&J”). It, in part, targets J&J’s active pharmaceutical ingredient (“API”) business. Once again, API manufacturing is in the spotlight. To read about the case and its potential impacts, check out my article at Policy & Medicine.
